VETERINARY TEAM REFERENCE

DEA & state schedules

Scheduling applies to the medication, not to the patient. This independent reference is not affiliated with the DEA.

Deracoxib

FEDERAL STATUS

Not federally scheduled

The identified ingredients in this entry are not listed in the reviewed federal schedules. Prescription-only status, product restrictions and state law are separate questions.

Federal source ↗

State / prescribing or dispensing jurisdiction

STATE STATUS

Select a jurisdiction

Choose the state relevant to prescribing or dispensing. Patient residence alone may not determine every applicable rule.

What each federal schedule means

Highlighted rows match the verified federal or selected state schedule. The schedule describes legal control and abuse potential; it does not rank clinical usefulness or establish a dose.

Federal Schedules I–V: meaning and practice implications
Schedule	Meaning and practice
I	High abuse potential; no currently accepted medical use in U.S. treatment; lacks accepted safety under medical supervision. In practice: Not available for routine veterinary prescribing. Authorized research is a separate pathway.
II	High abuse potential; accepted medical use, sometimes with severe restrictions; abuse can cause severe dependence. In practice: No prescription refills under federal law. Strict prescribing, security and record requirements apply.
III	Less abuse potential than I or II; accepted medical use; abuse can cause moderate or low physical dependence or high psychological dependence. In practice: Federal prescriptions allow up to five authorized refills within six months. State rules may be stricter.
IV	Lower abuse potential than III; accepted medical use; limited dependence risk relative to III. In practice: The same federal five-refill / six-month prescription limit applies. Controlled-drug handling still applies.
V	Lower abuse potential than IV; accepted medical use; limited dependence risk relative to IV. In practice: Still controlled. Check authorized refills and state limits; do not automatically apply the III–IV refill rule.

What this means for the chart

For a controlled medication, confirm the prescriber’s authority for the applicable schedule, the exact formulation and quantity, authorized refills, secure handling, and required inventory / dispensing records. Check the state’s veterinary rules and any prescription monitoring program (PDMP) requirements or exemptions.

A PDMP reporting requirement does not by itself make a drug scheduled. “Not federally scheduled” does not mean over the counter, risk-free, or exempt from state law. States may use additional categories, such as Schedule VI, outside the federal I–V system.

← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Deracoxib

A canine nonsteroidal anti-inflammatory drug used for osteoarthritis pain and inflammation and specified postoperative orthopedic or dental indications. The clinical indication determines which label instructions apply.

Coxib NSAIDProduct-specific clinical reference

Updated October 16, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Deramaxx controls canine osteoarthritis and orthopedic/dental postoperative pain. Never use in cats.

Key prescribing checks

Review prior NSAID reactions, hydration and gastrointestinal, renal and hepatic status before selecting treatment. Establish the monitoring plan with the prescribing veterinarian.
Avoid concurrent corticosteroids or other NSAIDs. Medication reconciliation should include recently discontinued drugs as well as current prescriptions.
Vomiting, diarrhea, reduced appetite or other suspected intolerance warrants prompt prescriber assessment. Flavored tablets need secure storage to prevent accidental ingestion.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Dogs

FDA-approved veterinary label

Osteoarthritis or orthopedic/dental postoperative pain and inflammation

Safety below four months unestablished.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Inhibits cyclooxygenase-dependent prostaglandin production.

Absorption, distribution, metabolism and elimination

Canine terminal half-life is approximately three hours at studied 2–3 mg/kg exposure; hepatic metabolism and fecal elimination predominate.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Deramaxx

U.S. canine chewable tablets.

Contraindications · when not to use

Known deracoxib hypersensitivity. Label also explicitly prohibits use in cats.

Precautions & monitoring

GI ulceration/perforation, renal and hepatic injury are possible; risk increases with dehydration, diuretics or existing renal/cardiovascular/hepatic dysfunction. Safety below four months or in breeding, pregnant/lactating dogs is unestablished. Monitor laboratory data and intolerance.

Safety sources checked: October 16, 2026. Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Vomiting, diarrhea, ulceration/perforation and renal/hepatic injury are possible.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

Selected product-label regimens — not a patient-specific prescription
Species & indication	Labeled regimen	Eligibility & source
DogsOsteoarthritisDeramaxx chewable tablets	1–2 mg/kg/day Oral · Once daily As needed; lowest effective dose/shortest duration	Safety below four months unestablished. Verify full dosing label ↗
DogsOrthopedic postoperative pain/inflammationDeramaxx chewable tablets	3–4 mg/kg/day Oral · Once daily Maximum seven days	Administer before procedure. Verify full dosing label ↗
DogsDental postoperative pain/inflammationDeramaxx chewable tablets	1–2 mg/kg/day Oral · Once daily Three days	First dose approximately one hour preoperatively. Verify full dosing label ↗

Below 12.5 mg use the 12 mg tablet, divisible to 6 mg; avoid splitting larger tablets for small doses.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Deramaxx

U.S. canine chewable tablets.

Avoid other NSAIDs or corticosteroids; consider washouts. Review nephrotoxic and highly protein-bound drugs and monitor compatibility.

Interaction source ↗

Monitoring

Baseline/periodic hematology and chemistry; monitor intolerance.

Client counseling

Avoid other NSAIDs/corticosteroids; report vomiting, bloody stools or appetite changes.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Follow the dispensed package storage instructions.

Brands, formulations & ingredient identity

Active ingredients

deracoxib

Deramaxx identifies deracoxib; it is not another name for carprofen, firocoxib or grapiprant. These drugs have distinct labels and cannot be exchanged by matching tablet strength.

The U.S. product is a flavored chewable tablet for dogs. Tablet strength, score and the ability to divide a tablet must be checked against the actual package.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Deramaxx

Formulation: Flavored chewable tablets
Label / product scope: Dogs

Canine prescription product; use the indication-specific label.

Product label / source ↗

References & review status

Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

01Elanco: Deramaxx product information and safety ↗02DailyMed: Deramaxx, updated January 2026 ↗

Search another medication or supplement →

Prescribing overview

Key prescribing checks

Uses by species

Dogs

Pharmacology & pharmacokinetics

Mechanism and clinical role

Absorption, distribution, metabolism and elimination

Contraindications & cautions

Contraindications · when not to use

Precautions & monitoring

Adverse effects

Dosing & administration

Drug & supplement interactions

Deramaxx

Monitoring

Client counseling

Storage & handling

Brands, formulations & ingredient identity

Active ingredients

Deramaxx

References & review status

Related Resources